GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evotec SE (NAS:EVO) » Definitions » Quality Rank

EVO (Evotec SE) Quality Rank


View and export this data going back to 2021. Start your Free Trial

What is Evotec SE Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Evotec SE Quality Rank Related Terms

Thank you for viewing the detailed overview of Evotec SE's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Evotec SE Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evotec SE (NAS:EVO) » Definitions » Quality Rank
Comparable Companies
XTER:B8FK ZTS XTER:MRK NSE:SUNPHARMA LSE:HLN TSE:4502 XSWX:GALD XSWX:SDZ XTAE:TEVA NSE:DIVISLAB VTRS HKSE:03692 SZSE:000538 NBIX NSE:TORNTPHARM BOM:543904 BOM:500124 TSE:4507 BOM:532321 BOM:500257
Traded in Other Exchanges
EVOTF:USA 1EVT:Italy EVTd:UK 0IRF:UK EVT:Germany EVT:Germany EVT:Germany EVT:Germany EVTA:Germany EVT:Bulgaria EVT:Austria
Address
Essener Bogen 7, Manfred Eigen Campus, Hamburg, DEU, 22419
Website
https://www.evotec.com
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.